MedTrace Logo

Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections

NCT05799716 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-04-05

No results posted yet for this study

Summary

The goal of this clinical trial is to learn about the benefit of IVIG in donor-derived infections and the potential immunomodulatory effect on transplanted organs. The main questions it aims to answer are:

1. How effective IVIG is in preventing donor-derived infections
2. Does IVIG has potential immunomodulatory effect on transplanted organs

Conditions

  • Viremia
  • Bacteremia
  • Acute Rejection of Renal Transplant

Interventions

DRUG

IVIG

0.5g/Kg

Sponsors & Collaborators

  • Shanghai Changzheng Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2024-04-01
Completion
2024-09-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05799716 on ClinicalTrials.gov